Alexion Pharmaceuticals, a wholly‑owned subsidiary of AstraZeneca plc (NYSE: AZN), announced that Klygefa (gefurulimab), from its rare disease portfolio, has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) as an add‑on to standard therapy for the treatment of generalized myasthenia gravis (gMG) in adults who are anti‑acetylcholine receptor (AChR) antibody‑positive.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | EMA (European Union) – CHMP |
| Opinion Type | Positive opinion recommending approval |
| Product | Klygefa (gefurulimab), complement C5 inhibitor |
| Indication | Add‑on to standard therapy for AChR antibody‑positive generalized myasthenia gravis in adults |
| Opinion Date | 18 September 2026 |
| Next Steps | CHMP opinion to be forwarded to the European Commission, which typically issues a final EU‑wide decision within approximately two months |
Drug Profile & Mechanism of Action
- Molecule: Gefurulimab, a complement C5 inhibitor that blocks terminal complement activation — the immune cascade that damages the neuromuscular junction in AChR antibody‑positive gMG.
- Innovation: A novel dual‑binding nanobody optimized for subcutaneous self‑administration, potentially freeing patients from infusion visits.
- Disease Context: gMG is a rare autoimmune disorder characterized by reduced muscle function and severe muscle weakness; AChR antibody positivity defines the population eligible under the recommended label.
- Portfolio Fit: Extends Alexion/AstraZeneca Rare Disease‘s leadership in complement‑mediated disease alongside Soliris (eculizumab) and Ultomiris (ravulizumab), both approved in gMG.
Clinical Evidence – PREVAIL Phase III Trial
| Endpoint | Result (Klygefa vs. Placebo) | Statistical Assessment |
|---|---|---|
| Change from Baseline in MG‑ADL Total Score at Week 26 (Primary) | Improvement vs. placebo | Treatment difference: –1.6 (95% CI: –2.4, –0.8), p < 0.0001 |
The pivotal PREVAIL Phase III trial met its primary endpoint, demonstrating statistically significant improvement from baseline in the Myasthenia Gravis Activities of Daily Living (MG‑ADL) total score at week 26 versus placebo. Secondary endpoints, dosing schedules, sample size, and safety data were not disclosed in the announcement.
Market Impact & Outlook
- Unmet Need in gMG: Many patients remain symptomatic despite standard therapy; an add‑on, self-administered biologic addresses both residual disease burden and treatment convenience.
- Competitive Landscape: Klygefa enters a fast‑growing AChR‑Ab+ gMG market that already includes C5 inhibitors Ultomiris and Soliris (Alexion/AstraZeneca) and UCB’s subcutaneous Zilbrysk (zilucoplan), alongside FcRn inhibitors Vyvgart (efgartigimod) and Rystiggo (rozanolixizumab).
- Commercial Synergy: Alexion’s established rare‑disease infrastructure and deep relationships with neurologists across Europe provide a ready launch platform.
- Regulatory Momentum: The European Commission decision is the final step for EU‑wide authorization; additional global filings were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, including the anticipated European Commission decision, clinical outcomes, and commercial expectations for Klygefa in generalized myasthenia gravis. Actual results may differ due to risks including final authorization conditions, label scope, reimbursement outcomes, competitive dynamics, and real‑world adoption.-Fineline Info & Tech
